Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.42 |
| ▸ | PDE4A | P27815 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11208112 | 1.00 | LMNA (0.48) | LMNAL3MBTL1PAX8USP2SLCO1B1 | |
| SCHEMBL11209579 | 1.00 | LMNA (0.48) | LMNAL3MBTL1PAX8USP2SLCO1B1 | |
| SCHEMBL2225961 | 1.00 | LMNA (0.48) | LMNAL3MBTL1PAX8USP2SLCO1B1 | |
| SCHEMBL7149767 | 1.00 | LMNA (0.48) | LMNAL3MBTL1PAX8USP2SLCO1B1 | |
| SCHEMBL7145241 | 1.00 | LMNA (0.48) | LMNAL3MBTL1PAX8USP2SLCO1B1 | |
| SCHEMBL1548302 | 0.93 | LMNA (0.52) | LMNAL3MBTL1PAX8USP2SLCO1B1 | |
| SCHEMBL3116850 | 0.93 | LMNA (0.52) | LMNAL3MBTL1PAX8USP2SLCO1B1 | |
| SCHEMBL2228073 | 0.93 | LMNA (0.52) | LMNAL3MBTL1PAX8USP2SLCO1B1 | |
| SCHEMBL22963142 | 0.93 | LMNA (0.52) | LMNAL3MBTL1PAX8USP2SLCO1B1 | |
| SCHEMBL2066243 | 0.93 | LMNA (0.52) | LMNAL3MBTL1PAX8USP2SLCO1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 262 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119846229-A | Biomarker for detecting diabetic macular edema, kit and application thereof | 首都医科大学附属北京同仁医院 | 2025-04-18 | — | — | CN | claimed |
| EP-3126517-B1 | MODIFIED CYTOSINE POLYNUCLEOTIDE OLIGOMERS AND METHODS | CEPHEID (US) | 2019-10-23 | — | — | EP | claimed |
| CN-106460058-B | Modified cytosine polynucleotide oligomers and methods | 赛沛 | 2019-07-09 | — | — | CN | claimed |
| EP-3126372-B1 | MODIFIED THYMINE POLYNUCLEOTIDE OLIGOMERS AND METHODS | CEPHEID (US) | 2019-02-06 | — | — | EP | claimed |
| CN-106459128-B | Modified thymine polynucleotide oligomers and methods | 赛沛 | 2018-05-29 | — | — | CN | claimed |
| US-9598456-B2 | Modified cytosine polynucleotide oligomers and methods | CEPHEID (US) | 2017-03-21 | — | — | US | claimed |
| US-9598455-B2 | Modified thymine polynucleotide oligomers and methods | CEPHEID (US) | 2017-03-21 | — | — | US | claimed |
| US-20120076781-A1 | METHODS OF TREATING CANCERS WITH HER3 ANTISENSE OLIGONUCLEOTIDES | SANTARIS PHARMA A/S (DK) | 2012-03-29 | — | — | US | claimed |
| CN-102395374-A | Methods of treating cancers with her3 antisense oligonucleotides | ENZON PHARMACEUTICALS INC | 2012-03-28 | — | — | CN | claimed |
| EP-2419110-A1 | METHODS OF TREATING CANCERS WITH HER3 ANTISENSE OLIGONUCLEOTIDES | Enzon Pharmaceuticals, Inc. (US) | 2012-02-22 | — | — | EP | claimed |
| CN-1822856-B | HCV vaccines | INTERCELL AG | 2010-04-28 | — | — | CN | claimed |
| US-20090203137-A1 | COMPOUNDS FOR THE MODULATION OF BETA-CATENIN EXPRESSION | SANTARIS PHARMA A/S (DK) | 2009-08-13 | — | — | US | claimed |
| US-20090192110-A1 | RNA ANTAGONIST COMPOUNDS FOR THE MODULATION OF PIK3CA EXPRESSION | SANTARIS PHARMA A/S | 2009-07-30 | — | — | US | claimed |
| US-20090181916-A1 | LNA ANTAGONISTS TARGETING THE ANDROGEN RECEPTOR | SANTARIS PHARMA A/S (DK) | 2009-07-16 | — | — | US | claimed |
| US-20090005335-A1 | COMPOUNDS FOR THE MODULATION OF BETA-CATENIN EXPRESSION | SANTARIS PHARMA A/S (DK) | 2009-01-01 | — | — | US | claimed |
| US-20080318894-A1 | RNA ANTAGONIST COMPOUNDS FOR THE MODULATION OF HER3 | SANTARIS PHARMA A/S (DK) | 2008-12-25 | — | — | US | claimed |
| CN-1822856-A | HCV vaccines | INTERCELL AG (AT) | 2006-08-23 | — | — | CN | claimed |
| CN-1771054-A | Improved vaccines | INTERCELL AG (AT) | 2006-05-10 | — | — | CN | claimed |
| CN-1434723-A | Immunostimulatory oligodeoxynucleotides | CISTEM BIOTECHNOLOGIES GMBH (AT) | 2003-08-06 | — | — | CN | claimed |
| US-5190783-A | Dietetics | NABISCO, INC. (US) | 1993-03-02 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090005335-A1 | COMPOUNDS FOR THE MODULATION OF BETA-CATENIN EXPRESSION | CTNNB1, CTNNA1, WNT1 | LMNA 673/4885L3MBTL1 741/4885PAX8 1961/4885 |
| US-20090192110-A1 | RNA ANTAGONIST COMPOUNDS FOR THE MODULATION OF PIK3CA EXPRESSION | PIK3CA, PIK3R4, PIK3R5 | LMNA 3031/4885L3MBTL1 992/4885PAX8 3436/4885 |
| US-20090203137-A1 | COMPOUNDS FOR THE MODULATION OF BETA-CATENIN EXPRESSION | CTNNB1, CTNNA1, WNT1 | LMNA 673/4885L3MBTL1 741/4885PAX8 1961/4885 |
| US-20090181916-A1 | LNA ANTAGONISTS TARGETING THE ANDROGEN RECEPTOR | AR, ESRRB, ESRRA | LMNA 1452/4885L3MBTL1 627/4885PAX8 868/4885 |
| US-20120076781-A1 | METHODS OF TREATING CANCERS WITH HER3 ANTISENSE OLIGONUCLEOTIDES | ERBB3, ERBB2, EGFR | LMNA 4174/4885L3MBTL1 1420/4885PAX8 1785/4885 |
| US-20080318894-A1 | RNA ANTAGONIST COMPOUNDS FOR THE MODULATION OF HER3 | ERBB3, EGFR, ERBB2 | LMNA 3823/4885L3MBTL1 1063/4885PAX8 3039/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.